New drug combo aims to shrink Hard-to-Treat lung tumors
NCT ID NCT07393555
First seen Feb 06, 2026 · Last updated May 14, 2026 · Updated 18 times
Summary
This study tests two drugs—sacituzumab govitecan and ivonescimab—alone or together in people with advanced non-small cell lung cancer that has certain gene changes (like EGFR or ALK) and has come back after prior treatment. The goal is to see if the combination works better than either drug alone at shrinking tumors or delaying cancer growth. About 117 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV LUNG CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.